Published in Cancer Prev Res (Phila) on March 01, 2011
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol (2015) 5.37
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem (2012) 1.69
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48
Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology (2011) 1.44
Potential role of HE4 in multimodal screening for epithelial ovarian cancer. J Natl Cancer Inst (2011) 1.39
Aberrant glycosylation associated with enzymes as cancer biomarkers. Clin Proteomics (2011) 1.36
Gold nanorods for ovarian cancer detection with photoacoustic imaging and resection guidance via Raman imaging in living mice. ACS Nano (2012) 1.24
Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res (Phila) (2011) 1.19
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer (2014) 1.10
Microfluidic integration for automated targeted proteomic assays. Proc Natl Acad Sci U S A (2012) 1.09
Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol (2012) 1.05
Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer. BMC Res Notes (2013) 1.04
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. Food Chem (2012) 1.02
The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics (2012) 1.02
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol (2011) 1.02
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res (2011) 0.95
Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. J Ovarian Res (2011) 0.95
Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma. J Biomed Opt (2012) 0.94
New paradigms in translational science research in cancer biomarkers. Transl Res (2012) 0.92
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci (2012) 0.92
A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clin Cancer Res (2016) 0.92
Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One (2011) 0.91
Cultivating cohort studies for observational translational research. Cancer Epidemiol Biomarkers Prev (2013) 0.90
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. J Natl Cancer Inst (2015) 0.90
Screening for cancer with molecular markers: progress comes with potential problems. Nat Rev Cancer (2012) 0.88
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prev Res (Phila) (2011) 0.87
Chaetoglobosin K inhibits tumor angiogenesis through downregulation of vascular epithelial growth factor-binding hypoxia-inducible factor 1α. Anticancer Drugs (2013) 0.86
Impact of screening test performance and cost on mortality reduction and cost-effectiveness of multimodal ovarian cancer screening. Cancer Prev Res (Phila) (2012) 0.86
Designing early detection programs for ovarian cancer. Ann Oncol (2011) 0.85
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci (2013) 0.84
Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry. Metabolites (2015) 0.83
Genomic biomarkers in predictive medicine: an interim analysis. EMBO Mol Med (2011) 0.83
Building multi-marker algorithms for disease prediction-the role of correlations among markers. Biomark Insights (2011) 0.83
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. Gynecol Oncol (2015) 0.82
Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera. PLoS One (2013) 0.81
Electrochemistry-based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnostics. Analyst (2015) 0.81
Array-based sensing using nanoparticles: an alternative approach for cancer diagnostics. Nanomedicine (Lond) (2014) 0.79
Serum protein profile at remission can accurately assess therapeutic outcomes and survival for serous ovarian cancer. PLoS One (2013) 0.79
Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer. Int J Mol Sci (2014) 0.79
Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health (2013) 0.78
Identification of five serum protein markers for detection of ovarian cancer by antibody arrays. PLoS One (2013) 0.77
Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. J Transl Med (2012) 0.77
Protein Z: A putative novel biomarker for early detection of ovarian cancer. Int J Cancer (2016) 0.77
EPIC Early Detection of Ovarian Cancer. Clin Cancer Res (2016) 0.75
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol (2017) 0.75
Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol (2014) 0.75
HIF-1α binding to AEG-1 promoter induced upregulated AEG-1 expression associated with metastasis in ovarian cancer. Cancer Med (2017) 0.75
Novel risk models for early detection and screening of ovarian cancer. Oncotarget (2016) 0.75
Laboratory detective work identifies a mishandling problem in sample aliquoting. Biopreserv Biobank (2014) 0.75
Application of proteomics to cancer early detection. Cancer J (2011) 0.75
Can CA-125 predict lymph node metastasis in epithelial ovarian cancers in Turkish population? Dis Markers (2014) 0.75
Identification of Differentially Expressed Proteins in the Serum of Colorectal Cancer Patients Using 2D-DIGE Proteomics Analysis. Pathol Oncol Res (2016) 0.75
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics (1988) 70.41
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Phases of biomarker development for early detection of cancer. J Natl Cancer Inst (2001) 10.37
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials (2000) 5.37
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics (2004) 4.58
Bias as a threat to the validity of cancer molecular-marker research. Nat Rev Cancer (2005) 4.43
Translation of highly promising basic science research into clinical applications. Am J Med (2003) 3.74
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A (2005) 3.22
Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 2.90
Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol (2009) 2.86
Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol (2003) 2.58
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS One (2008) 1.93
Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev (2006) 1.36
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem (2008) 1.31
Effects of blood collection conditions on ovarian cancer serum markers. PLoS One (2007) 1.27
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Epidemiology informing clinical practice: from bills of mortality to population laboratories. Nat Clin Pract Oncol (2005) 1.02
Proteomic patterns to identify ovarian cancer: 3 years on. Expert Rev Mol Diagn (2004) 0.97
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 11.07
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood (2005) 8.37
50-year trends in smoking-related mortality in the United States. N Engl J Med (2013) 7.80
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
The case for early detection. Nat Rev Cancer (2003) 6.96
Reporting participation in epidemiologic studies: a survey of practice. Am J Epidemiol (2005) 6.52
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect (2004) 6.43
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med (2004) 6.42
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst (2002) 6.28
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood (2009) 5.69
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Smoking and mortality--beyond established causes. N Engl J Med (2015) 5.54
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA (2006) 4.87
Dicer function is essential for lung epithelium morphogenesis. Proc Natl Acad Sci U S A (2006) 4.87
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer (2007) 4.76
ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst (2009) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med (2008) 4.55
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med (2004) 4.50
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet (2016) 4.49
Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med (2004) 4.49
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA (2002) 4.39
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res (2006) 4.32
Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA (2002) 4.32
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30